Boston Scientific Acquires Penumbra, Expanding Neurovascular Portfolio – Merger Arbitrage Mondays

Penumbra, Inc. (PEN): $350.78

Market Cap: $13.74B

Deal Size: $14.5B

Boston Scientific (BSX) entered a merger agreement on January 15, 2026, to acquire medtech firm Penumbra in a deal valued at $14.5 billion to expand its presence in the treatment of blood clots and strokes.

The deal is Boston Scientific’s biggest acquisition in the past 20 years and the first major healthcare transaction of 2026. Analysts and industry insiders expect many more large mergers this year, as companies take advantage of easier regulations and lower interest rates to strengthen their portfolios.

Only plus or premium subscribers can access this post. Subscribe today.